The combination of pemetrexed and cisplatin appeared safe and effective in women with advanced, persistent or recurrent carcinoma of the cervix, according to results of a phase 2 trial. “This ...
The FDA this week approved pemetrexed in combination with cisplatin as first-line therapy for locally advanced metastatic non–small cell lung cancer in patients with nonsquamous history, according to ...
The FDA has approved a generic form of the intravenous chemotherapy pemetrexed for use by itself in patients with locally advanced or metastatic non-squamous non-small cell lung cancer that has not ...
Pemetrexed is an (antifolate) antineoplastic agent, prescribed for mesothelioma (cancer that develops from the protective lining of the internal tissues) and certain types of non-small cell lung ...
Learn everything you need to know about Pemetrexed-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...
Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: More Questions Than Answers Ramalingam et al 1 reported the results of a phase III trial, ECOG-ACRIN 5508, which compared ...
The median OS was not reached at the time of the data cut-off in the pembrolizumab plus chemotherapy arm and was 11.3 months for those in the chemotherapy arm. The Food and Drug Administration (FDA) ...
June 8, 2011 (Chicago, Illinois) — Maintenance therapy with the chemotherapy drug pemetrexed (Alimta, Eli Lilly) improves progression-free survival in patients with advanced nonsquamous nonsmall-cell ...
Fifty patients were enrolled and received treatment. The median follow-up was 13.0 months, and the median number of treatment cycles was seven (range, one to 51). Thirty patients (60%) completed ≥ six ...
The Appraisal Committee (appendix A) considered evidence submitted by the manufacturer of pemetrexed and a review of this submission by the Evidence Review Group (ERG; appendix B). The Institute and ...
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the Pemetrexed market was valued at US$ 2,062.5 million in 2017, and is projected to exhibit a CAGR of 1.3% over the forecast period ...
"The claim that pemetrexed is superior in adenocarcinoma is one that is not supported by the US FDA [US Food and Drug Administration] and is not supported by a careful consideration of the evidence," ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results